Tiret L, Bonnardeaux A, Poirier O, Ricard S, Marques-Vidal P, Evans A, Arveiler D, Luc G, Kee F, Ducimetière P
INSERM U258, Paris, France.
Lancet. 1994 Oct 1;344(8927):910-3. doi: 10.1016/s0140-6736(94)92268-3.
We reported from our previous multicentre case-control study that the deletion (D) polymorphism of the gene encoding angiotensin-converting enzyme (ACE) was associated with increased risk of myocardial infarction. The main function of ACE is to convert angiotensin I into angiotensin II, which exerts its known cellular actions through the angiotensin II AT1 receptor subtype (AGT1R). We have now investigated the role of a common polymorphism of the AT1 receptor gene (an A-->C transversion at position 1166 of AGT1R) and looked for an interaction between ACE and AGT1R gene polymorphisms on the risk of myocardial infarction. We analysed DNA from 613 patients with myocardial infarction and 723 age-matched population controls. We found a significant interaction between ACE and AGT1R gene polymorphisms; the odds ratio for myocardial infarction associated with the ACE DD genotype was 1.05 (95% CI 0.75-1.49) for subjects without the AGT1R C allele, 1.52 (1.06-2.18) in AC heterozygotes, and 3.95 (1.26-12.4) in CC homozygotes (test for trend, p < 0.02). Among patients defined as low risk by traditional risk factors (serum apolipoprotein B < 1.25 g/L, body-mass index < 26 kg/m2) the interaction was even stronger (odds ratios 1.64 [0.68-3.92], 7.03 [2.61-19.0], and 13.3 [p = 0.05], respectively). These findings, if confirmed, could have clinical implications for the prevention and treatment of coronary heart disease.
我们在之前的多中心病例对照研究中报告称,编码血管紧张素转换酶(ACE)的基因缺失(D)多态性与心肌梗死风险增加相关。ACE的主要功能是将血管紧张素I转化为血管紧张素II,血管紧张素II通过血管紧张素II 1型受体亚型(AGT1R)发挥其已知的细胞作用。我们现在研究了AGT1受体基因常见多态性(AGT1R第1166位的A→C转换)的作用,并寻找ACE和AGT1R基因多态性在心肌梗死风险上的相互作用。我们分析了613例心肌梗死患者和723例年龄匹配的人群对照的DNA。我们发现ACE和AGT1R基因多态性之间存在显著相互作用;对于没有AGT1R C等位基因的受试者,与ACE DD基因型相关的心肌梗死优势比为1.05(95%可信区间0.75 - 1.49),AC杂合子为1.52(1.06 - 2.18),CC纯合子为3.9(1.26 - 12.4)(趋势检验,p < 0.02)。在由传统危险因素定义为低风险的患者中(血清载脂蛋白B < 1.25 g/L,体重指数 < 26 kg/m2),这种相互作用更强(优势比分别为1.64 [0.68 - 3.92]、7.03 [2.61 - 19.0]和13.3 [p = 0.05])。这些发现如果得到证实,可能对冠心病的预防和治疗具有临床意义。